Exhibiting at RESI – Connect with Top Life Science Startups

April 13, 2023April 13, 2023 ~ Next Phase Admin ~ Leave a comment

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Redefining Early Stage Investments (the RESI conference series) is a unique gathering. Several hundred startup companies representing cutting-edge technologies from across the verticals of the life sciences attend RESI to meet the huge turnout of investors and to learn about the services that will help them develop and grow their companies.

Visibility and brand recognition with companies that will be raising funds and initiating R&D, pre-clinical, and clinical activities soon is key to add to the leads funnel. RESI gives service providers the chance to have an exhibit table right in the middle of all the activity, as well as a presence online, in our newsletter, and in the program guide.

In addition to meeting the startups, there is the opportunity to meet some of the hundreds of investors and licensing partners that have extensive portfolios of companies in need of crucial services.

For more information, reach out to the LSN Business Development Team!

Life Science Nation Business Development Team
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast (USA)

Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Cameron Hurlburt Manager of Business Development Book a Meeting Email Me

Preparing for the Innovator’s Pitch Challenge (IPC) at RESI Boston

April 13, 2023 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

LSN is once again featuring The Innovator’s Pitch Challenge (IPC) at the upcoming in-person RESI Boston on June 5. The IPC has been immensely popular among life science entrepreneurs and startup founders that attend RESI. The selected finalists will be grouped into sector-themed pitch sessions, and each company will have 4 minutes to present and 8 minutes for Q&A with an investor panel. The IPC offers a unique opportunity for founders and CEOs to engage directly with a panel of seasoned investors, who are specialized in the sectors that they judge for, so that the feedback and questions can be highly practical and constructive for the participants. The IPC is not only popular among startups, it is also valued by many active investors as an efficient way to engage with startups within their sector of interest. Whether you are a startup CEO or an investor, we welcome you to participate in IPC at our upcoming conference.

With two months left until RESI Boston, LSN is organizing an online workshop to help participants prepare for the IPC, ensuring that they can leverage the opportunity to the fullest extent. Please see below for the workshop schedule, and don’t forget to submit your application for the IPC before April 21, the final deadline. We highly recommend you to apply as early as possible, so you will have more time to prepare and maximize your experience. I look forward to seeing you at our webinar next week.

Hot Investor Mandate: Asia-Based Evergreen Fund Invests in Early Clinical Stage Biotech and Medtech, Investing Up to $10M in Companies in Sizable Markets

April 13, 2023 ~ Next Phase Admin ~ Leave a comment

An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.

The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.

The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm & Venture Builder Actively Seeks Therapeutics Opportunities, Investing From as Early as Discovery Phase

April 13, 2023 ~ Next Phase Admin ~ Leave a comment

An investor and venture builder based in the US invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC’s Inaugural Fund Invests in Therapeutics, Diagnostics, and Life Science Tools, Can Also Invest in Likeminded Funds

April 13, 2023 ~ Next Phase Admin ~ Leave a comment

An emerging venture fund is currently for their first fund and will invest from seed to early stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $0.5-3 Million, and may participate as a fund of funds. The firm is focused on investments in Southern California, but can invest in companies nationwide.

Within therapeutics, the firm is interested in small molecules, biologics, RNA platforms, and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases.

The firm is willing to lead or co-invest, is an active investor, and will request board participation after an investment in helping the entrepreneur and company improve their chances for seeking subsequent financings and building value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Supports Life Science Technologies Through Funding and Company Formation, Focusing on North America-Based Companies

April 13, 2023 ~ Next Phase Admin ~ Leave a comment

A venture capital investment firm has a unique model that takes early-stage pre-company technologies and supports them in company formation. The firm invests in early stage pre-proof-of-concept companies that may have a longer development timeline. The firm provides investment and – dependent on the company – advisory roles to support the company to its next step in development. The firm typically invests around $250,000 per company, and currently manages a low to mid-million dollar fund, though has access to a greater market flow. The firm currently holds a portfolio of 11-12 deals, and is seeking to add 6-7 deals in their pipeline. The firm leads investments for small early stage companies, and co-invests into deals that are greater than $500K. Even while making seed investments, the firm has the ability to syndicate deals and provide value with an advisory role. The firm focuses on companies based in North America (USA & Canada), and has previously made investments in Texas, Ohio, North and South Carolina, Florida, and Canada, among others.

The firm currently has 4 clusters of companies, each separated by the following categories: pet health; hospital channeled products (hospital supply); rehabilitation and mobility; and hospital acquired infection sterilization. While the firm is constantly finding technology in these four clusters, The firm is open to look at all life science technologies outside of these clusters, including biotech therapeutics (especially biologics and regenerative medicine), medical devices, and diagnostics. For medical devices, the firm looks mainly at 510K consumer products (included plastic surgery), and would only invest in PMA devices under the right circumstances as a minor player/syndicate. The firm typically invests in products in the pre-clinical, in-development stage when the product is still an idea.

The firm prefers an experienced team in the space, and will help handpick the management team around the deal. The firm typically takes a board seat after an investment, especially as the first ones in for seed stage companies. The firm will likely invest in products with no IP or prototype, and will put the firm’s network of engineers to support the product and work with the IP.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The Right Place to Meet with Real Investors – Here’s Why Startups Attend RESI

April 6, 2023April 6, 2023 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI continues to be successful with a global gathering of early-stage startups, as well as the investors and strategic partners looking to invest in them. Participants from more than 30 countries on 5 continents attended RESI in the past year. Whether it is an in-person or a virtual, each RESI has 1,000+ partnering meetings booked. Individual companies have booked up to 40 meetings over the course of the conference, with more than 75% of meetings booked occurring between companies and investors.

RESI-Partnering-Meeting-Breakdown

In addition to an extremely active partnering platform, the panels, workshops, and pitch sessions are well-attended and dynamic, with enthusiastic audience participation. We’ll continue to serve life science startups all this great content and provide a wonderful partnering experience in the upcoming RESI Boston June 5-7, with one day in person (June 5) at The Westin Copley Place in Boston, followed by two days (June 6-7) of virtual partnering only. Make sure to register by Friday, April 7th for Super Early Bird tickets to save $500!